anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In clinical trials and worldwide postmarketing experience there were reports of nebivolol overdose. The most common signs and symptoms associated with nebivolol overdosage are bradycardia and hypotension. Other important adverse reactions reported with nebivolol overdose include cardiac failure, dizziness, hypoglycemia, fatigue and vomiting. Other adverse reactions associated with β-blocker overdose include bronchospasm and heart block.

The largest known ingestion of nebivolol worldwide involved a patient who ingested up to 500 mg of nebivolol along with several 100 mg tablets of acetylsalicylic acid in a suicide attempt. The patient experienced hyperhydrosis, pallor, depressed level of consciousness, hypokinesia, hypotension, sinus bradycardia, hypoglycemia, hypokalemia, respiratory failure and vomiting. The patient recovered.

Because of extensive drug binding to plasma proteins, hemodialysis is not expected to enhance nebivolol clearance.

If overdose occurs, provide general supportive and specific symptomatic treatment. Based on expected pharmacologic actions and recommendations for other β-blockers, consider the following general measures, including stopping nebivolol tablets, when clinically warranted:

Bradycardia: Administer IV atropine. If the response is inadequate, isoproterenol or another agent with positive chronotropic properties may be given cautiously. Under some circumstances, transthoracic or transvenous pacemaker placement may be necessary.

Hypotension: Administer IV fluids and vasopressors. Intravenous glucagon may be useful.

Heart Block (second or third degree): Monitor and treat with isoproterenol infusion. Under some circumstances, transthoracic or transvenous pacemaker placement may be necessary.

Congestive Heart Failure: Initiate therapy with digitalis glycoside and diuretics. In certain cases, consider the use of inotropic and vasodilating agents.

Bronchospasm: Administer bronchodilator therapy such as a short acting inhaled β2-agonist and/or aminophylline.

Hypoglycemia: Administer IV glucose. Repeated doses of IV glucose or possibly glucagon may be required.

Supportive measures should continue until clinical stability is achieved. The half-life of low doses of nebivolol is 12 to 19 hours.

Call the National Poison Control Center (800-222-1222) for the most current information on β- blocker overdose treatment.
BACKGROUND: Low back pain (LBP) is one of the most common musculoskeletal conditions. People with LBP often display changes of neuromuscular control and trunk mechanical properties, including trunk stiffness. Although a few individual studies have examined back muscle stiffness in individuals with LBP, a synthesis of the evidence appears to be lacking. Therefore, the aim of this systematic review with meta-analysis was to synthesize and evaluate the available literature investigating back muscle stiffness in association with LBP.
METHODS: We conducted a systematic review of the literature according to the PRISMA guidelines. We searched Pubmed, Scopus, Web of Science and ScienceDirect for studies, that compared back muscle stiffness, measured either by ultrasound-based elastography or myotonometry, between individuals with and without LBP. Pooled data of the included studies were presented descriptively. Additionally, we performed two meta-analyses to calculate the standardized mean difference between the two groups for resting stiffness of the multifidus and erector spinae muscle. For both meta-analyses, the random effect model was used and the weight of individual studies was calculated using the inverse-variance method. The quality of the included studies was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Analytical Cross-Sectional studies. Furthermore, the certainty of evidence was evaluated using the GRADE approach.
RESULTS: Nine studies were included in our systematic review. Our results suggest that individuals with LBP have higher stiffness of the multifidus (SMD = 0.48, 95% CI: 0.15 - 0.81, p < 0.01; I2 = 48 %, p = 0.11) and erector spinae at rest (SMD = 0.37, 95% CI: 0.11 - 0.62, p < 0.01; I2 = 39 %, p = 0.14) compared to asymptomatic controls. On the other hand, the evidence regarding muscle stiffness during submaximal contractions is somewhat contradictory.
CONCLUSIONS: Based on the findings of this systematic review we conclude that people with LBP may have higher back muscle stiffness compared to asymptomatic controls. Addressing muscle stiffness might represent an important goal of LBP treatment. Nevertheless, our findings should be interpreted with extreme caution due to a limited quality of evidence, small number of included studies and differences in measurement methodology.
The present invention discloses the use of TRAP per se as an active ingredient for the manufacture of a medicament for the treatment of  Staphylococcus aureus  infection. An exogenous TRAP (native TRAP or recombinant TRAP) per se can effectively inhibit the production of  Staphylococcus aureus  exotoxins, thereby reducing the pathogenicity of  Staphylococcus aureus.  In addition, a medicament comprising TRAP also stimulates the production of corresponding antibodies in human body at the time when it is used to treat  Staphylococcus aureus  infections, and these antibodies can further inhibit the production of  Staphylococcus aureus  exotoxins. Such double actions increase the effects of medicament and provide a novel medicament action mode. Moreover, since TRAP functions merely to the toxicity of bacteria but does not affect the growth of bacteria, it cannot make bacteria readily develop drug resistance, and also effective to drug resistant  Staphylococcus aureus.  Moreover, no homologous sequence of the TRAP proteins of the present invention is found in human genome, so that the medicaments of TRAP cannot cause human immunologic diseases.
Smoking has harmful effects on nearly every organ of the body and causes seven million deaths worldwide every year. Although the prevalence of daily cigarette smoking in Hong Kong has decreased from 23.3% in 1982 to 10.5 % in 2015, there are still 641,300 daily smokers and 400,000 hospitalisations per year that are attributable to smoking. Having a disease and requiring medical attention present an excellent 'teachable moment' and opportunity for initiating smoking cessation in patients, because they will be more likely to be motivated to alter their habits and improve their health. However, cigarette smoking is addictive and quitting is very difficult, with a high rate of relapse, particularly among patients with chronic diseases.

During the past decade, the investigators have conducted several trials on promoting smoking cessation to smokers with chronic diseases, including cardiac, type 2 diabetes mellitus, and cancer. It is found that many smokers with chronic diseases had a long smoking history, high nicotine dependency, no quit attempt, and no intention to quit. Results of these studies indicated that about 68% smokers with cardiac diseases, 70% with diabetes mellitus and 73% with cancer recruited in Special Out-Patient Clinics (SOPC) were still in the pre-contemplation stage. This revealed that most Hong Kong smokers with chronic diseases perceived more barriers in quitting than the benefits of quitting. Nevertheless, our previous smoking cessation interventions mostly focused on using brief interventions including stage-matched smoking cessation advice. Such interventions could be too brief and inadequate to make a great impact on such smokers. Moreover, the investigators found that using strong warnings to communicate the risk of continued smoking might not be accepted by some of them. Hence, the investigators need to develop and evaluate a more innovative intervention to enhance the effectiveness in promoting smoking cessation for smokers with chronic diseases. Most importantly, the new strategy should have a good potential implementation in many clinical settings.

Smoking has been found to be associated with physical inactivity, unhealthy diet, and drinking. The interrelationship of health behaviours suggests that there could be a higher level of attribute that determines such behaviours together. Our previous studies showed that people with a general intention to promote their health are more likely to engage in desirable health-related lifestyle practices. In addition, research results showed that people once engaged in any desirable health-related lifestyle practices would progressively move to later stages of change for other health behaviours. Based on this concept, a general health promotion approach will be used to motivate smokers with intention to promote health to first engage in any desirable health-related lifestyle practices that are chosen by individual smokers, such as regular physical activity and healthy diet. It is anticipated that once they are engaged in any desirable health-related lifestyle practice they will eventually be more motivated to quit smoking.
Chromium is an essential nutrient for the maintenance of normal glucose tolerance and its deficiency causes insulin resistance. Chromium administration has also been shown in several studies to lower glucose and insulin levels in patients with type 2 diabetes. Moreover, studies in humans, animals and cell culture indicate that chromium enhances insulin signaling. While these studies suggest that chromium administration increases insulin sensitivity, it has not been directly demonstrated that chromium has an effect in well defined insulin resistant subjects independent of hyperglycemia. Accordingly, we propose to perform a placebo-controlled study of chromium picolinate administration in a cohort of non-obese, non-diabetic, insulin resistant subjects. The insulin sensitivity of 80 subjects will be measured by a euglycemic insulin clamp. Approximately 40 insulin resistant subjects will be randomized to 16 weeks of therapy with either 500 ug twice a day of chromium picolinate or placebo. To quantitate the chromium-induced improvements, euglycemic hyperinsulinemic clamps to evaluate insulin sensitivity, OGTT using deuterated glucose to evaluate glycolytic glucose disposal, and muscle biopsies to evaluate insulin signaling pathways, will be performed before and after treatment. We believe these studies will (1) confirm the beneficial effect of chromium on insulin sensitivity; (2) further our understanding of the molecular mechanisms of chromium action; and (3) because these insulin resistant subjects are at risk for the development of type 2 diabetes, the Metabolic Syndrome, and coronary artery disease (CAD), a demonstration of the beneficial effects of chromium on insulin action could ultimately have important public health consequences.
1446781 4-Hydroxy-3,5-dialkyl phenyl propionic acid and derivatives thereof HOECHST AG 20 Aug 1973 [18 Aug 1972] 39286/73 Heading C2C [Also in Division A5] Phenyl propionic acid derivatives of the formulae wherein R 1  and R 2  represent C 1-8  alkyl radicals, R 3  is a C 2-12  saturated hydrocarbon radical having n free bonds, X is OH, C 1-18  alkoxy, phenalkoxy with 1 to 4 carbon atoms in the alkyl group, C 5-8  cycloalkoxy or a group -NR 4 R 5  where R 4  is C 1-18  alkyl or benzyl and R 5  is H or R 4  and R 5  together with the nitrogen atom form a 6-membered heterocyclic ring which may contain an oxygen atom as a further hetero atom and n is an integer from 2 to 4, have hypolipaemic and hypoglycaemic activity and may be employed as ingredients of pharmaceutical compositions (see Division A5). In the examples of the preparation of the phenyl propionic acid derivatives, acrylonitrile is reacted with 2,6-di-tert.-butyl phenol in the presence of potassium and dry tert. butanol to yield 4- hydroxy - 3,5 - di. - tert. - butyl - phenyl propionitrile and this is hydrolysed to the 4-hydroxy- 3,5-di-tert.-butyl-phenyl propionic acid. From the acid there are prepared the methyl, n-butyl, octadecyl, benzyl, cyclohexyl, phenylethyl and pentaerythrityl esters, the ethylene glycol diester and the butylamide, benzylamide and morpholide.
OBJECTIVES: The reproductive desire of women following genital fistula repair surgery is complex, varied and often not addressed, although it carries significant consequences. The aim of this study was to better understand the fertility desires and sexual behaviours of women who recently underwent surgical repair of a genital fistula.
METHODS: This is a secondary analysis of a retrospective cohort study designed to assess the effectiveness of Beyond Fistula, a reintegration programme for women recovering from genital fistula surgery in Eldoret, Kenya. One hundred women who participated in the Beyond Fistula programme between 2013 and 2019 were interviewed in person regarding future fertility desire, current sexual behaviour and contraceptive use.
RESULTS: Among the 79 reproductive-aged women included in this study, 63.3% reported no future desire for pregnancy. Those that desired another pregnancy were significantly younger (48.3% were 18-29 years old vs. 66.0% were 35 years old or more, p = 0.004), had fewer living children (70% had 0-2 children vs. 56% had 3 or more children, p < 0.001), and a lower level of food insecurity (27.6% reported no to marginal insecurity vs. 14%, p = 0.014). Current sexual activity was marginally different between women who did and did not desire future pregnancy (82.8% vs. 66.0%, p = 0.053). Of the 50 women in our study who did not desire pregnancy, 62.0% were sexually active and of these, only 38.7% were preventing pregnancy. Lack of knowledge and access to methods were most commonly cited as barriers to use.
CONCLUSIONS: Many women recovering from genital fistula surgery do not desire pregnancy and are sexually active but are not using a method to prevent pregnancy. The potential for post-surgical reintegration programmes to address education and access to contraception is a vital and unmet need to promote reproductive empowerment in this population of women as they reestablish their lives.
The methods currently known for the preparation of meclocycline are unsatisfactory as secondary products which are difficult and costly to remove form during different stages of the synthesis. One of the critical points for the synthesis is dehalogenation of the molecule at the 11 position. We have discovered that by performing this stage in a suitable manner, different from those described previously, an appreciably purer compound is obtained which can be more readily increased to a level of purity for pharmaceutical use. Meclocycline, i.e. 7-chloro-6-methylene-5-oxytetracycline (I) <IMAGE> is the drug of choice for the treatment of skin infections because its antibacterial activity against both gram-positive and gram-negative strains is truly very high, its toxicity is low, its absorption through the skin is virtually zero, and one reason for this lack of absorption both via the skin and via the gastrointestinal tract may be its very great capacity to bind with macromolecules present on the absorption surface. In addition to the absorption spectrum, chemical- therapeutic activity and stability are not affected by exposure to UV rays.
OBJECTIVES: I. Determine the maximum tolerated dose of ganciclovir administered IV every 12 hours for 7 days in combination with adenovirus RSV-TK administered by direct intralesional injection in patients with cutaneous or subcutaneous metastatic malignant melanoma. II. Determine the dose limiting toxicities of this regimen in this patient population. III. Evaluate the response (both local and at distant metastatic sites), duration of response, response by ganciclovir dose, and any impact local treatment with adenovirus RSV-TK and ganciclovir "suicide" gene therapy may have on overall survival in these patients.

OUTLINE: This is a dose escalation study of ganciclovir. Patients are stratified according to response of the index lesion and other metastatic disease sites. Patients receive an intratumoral injection of adenovirus RSV-TK on day 1. Ganciclovir IV is administered every 12 hours on days 3-10 for a total of 14 doses. Patients sustaining a partial response (PR) or complete response (CR) may be retreated 2 weeks after documented PR or CR. Cohorts of 3-6 patients receive escalating doses of ganciclovir until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicities. Patients are followed at 3 weeks, 4 weeks, 60 days, then every 2 months for 6 months, and then every 3 months for 1.5 years.

PROJECTED ACCRUAL: A maximum of 27 patients will be accrued for this study.
Patients receive AU409 PO on study. Patients also undergo CT or MRI and collection of blood samples throughout the trial.
FIELD: chemistry.SUBSTANCE: method is characterized by that praziquantel and albendazole are mixed and dissolved in dimethylsulphoxide. Obtained mixture is dispersed into sodium carboxymethyl cellulose. After evaporation of dimethylsulphoxide, microcapsules are formed and dried to equilibrium moisture content. Then, a microcapsule shell is applied in a drum-type mixer, the latter including E472a plasticiser, aerosil-300 water repellent and 2C acid red dye. Carbinol and cyclohexanol are added. Obtained suspension is filtered and dried.EFFECT: invention provides preparing an agent for treating fishes in helminthiases.1 cl, 5 ex
PURPOSE:To eliminate effectively an offensive smell and foul breath, by using an extract of natural plant beefsteak plant with an alcohol as a food deodorant. CONSTITUTION:A deodorant obtained by pulverizing natural beefsteak plant Perilla frutescens discolor or Perilla frutescens Britt. var. crispa Decne dried by heating or freezing, extracting the resultant powder with 85-99vol./vol% ethyl alcohol at 10-30 deg.C, and using the resultant extract of the natural beefsteak plant with the alcohol as a food deodorant, e.g. by adding to a garlic or a food contaning the same or toffees for preventing foul breath to eliminate the offensive smell of the food or foul breath. The deodorant component in the beefsteak plant can be selectively extracted in high quality and yield by the above- mentioned method.
FIELD: medicine, stomatology. SUBSTANCE: invention relates to the production of the curative-prophylactic composition used for teeth treatment. Composition has an abrasive material - synthetic finely dispersed amorphous silicon dioxide, surface-active substance - sodium lauryl sulfate, moisture retaining substances, dye - pigmented titanium dioxide, sweetening agent - saccharin and water. Composition has additionally hydroxyapatite paste consisting of water and hydroxyapatite (particle size is 0.0001-2.0 mcm), milfoil and nettle aqueous-alcohol-glycerol extracts, sodium carboxymethylcellulose and food benzoate sodium. Moisture retaining substances are glycerol and sorbitol. Components of the composition are taken at the definite quantitative ratio. Composition eliminates gum bleeding, shows anti-inflammatory effect, normalizes an acid-alkaline balance at regular using. EFFECT: enhanced effectiveness of the composition. 1 tbl
UNLABELLED: Hospital-acquired infections (HAIs) represent one of the significant causes of morbidity and mortality worldwide, and controlling pathogens in the hospital environment is of great importance. Currently, the standard disinfection method in the hospital environment is chemical disinfection. However, disinfectants are usually not used strictly according to the label, making them less effective in disinfection. Therefore, there is an emergent need to find a better approach that can be used in hospitals to control pathogenic bacteria in the clinical environment. Bacteriophages (phages) are effective in killing bacteria and have been applied in the treatment of bacterial infections but have not received enough attention regarding the control of contamination in the clinical environment. In this study, we found that various phages remain active in the presence of chemical disinfectants. Moreover, the combined use of specific phages and chemical disinfectants is more effective in removing bacterial biofilms and eliminating bacteria on hard surfaces. Thus, this proof-of-concept study indicates that adding phages directly to chemical disinfectants might be an effective and economical approach to enhance clinical environment disinfection.
IMPORTANCE: In this study, we investigated whether the combination of bacteriophages and chemical disinfectants can enhance the efficacy of reducing bacterial contamination on hard surfaces in the clinical setting. We found that specific phages are active in chemical disinfectants and that the combined use of phages and chemical disinfectants was highly effective in reducing bacterial presence on hard surfaces. As a proof-of-concept, we demonstrated that adding specific phages directly to chemical disinfectants is an effective and cost-efficient strategy for clinical environment disinfection.
Colorectal carcinoma (CRC) is the third most common cancer and the fourth deadliest. Despite recent advances in screening methods and preoperative imaging techniques, the threat of colorectal cancer remains at an all-time high. Moreover, even after curative treatment, disease recurrence occurs in up to 40% of all cases. However, half of patients with recurrent disease do not register any distant metastases. Therefore, much effort should be expended in identifying and evaluating these patients, as many of them are suitable candidates for en bloc resections with perioperative chemoradiation. In fact, it has recently been found that overall survival benefits greatly from extended resections, provided that free margins are achieved intraoperatively. In this case report, we will present a case of locally advanced recurrent colorectal cancer invading the aortoiliac axis and our approach to achieving a R0 resection.
Compsn. to alleviate proliferative skin diseases contains a pharmacologically acceptable carrier and >=1 cpd. of formula (I) or acid addn. salts: (where R = 1-4C alkyl or 3-6C cycloalkyl; and R1 = H, acetyl or propionyl). The compsn. can be used to treat e.g. psoriasis, atropical dermatitis, non-specific dermatitis, primary irritant contact dermatitis, allergic contact dermatitis, basal and squamous cell carcinomas of the skin, lamellar ichthyosis, non-malign keratosis, acne and dandruff in humans and atopical dermatitis and mange in domestic animals. Suitable oral doses are 2-30 mg taken 1-4 times daily, but higher doses for psoriasis are pref.
After a 4-week period of baseline monitoring, Acthar gel will be administered by intramuscular or subcutaneous injection. Initial dosing will be 40 U every 72 hours (or twice per week) for 4 weeks. Dosage will then be increased to 80 U with similar frequency for 8 weeks and up to 16 weeks.
One of the most severe adverse effects is hyperkalemia (see CONTRAINDICATIONS, WARNINGS, and OVERDOSAGE). Gastrointestinal bleeding and ulceration have been reported in patients treated with Micro-K® Extencaps® (see CONTRAINDICATIONS and WARNINGS). In addition to gastrointestinal bleeding and ulceration, perforation and obstruction have been reported in patients treated with other solid KCI dosage forms, and may occur with Micro-K® Extencaps®. 

The most common adverse reactions to the oral potassium salts are nausea, vomiting, flatulence, abdominal discomfort, and diarrhea. These symptoms are due to irritation of the gastrointestinal tract and are best managed by taking the dose with meals, or reducing the amount taken at one time. Skin rash has been reported rarely with potassium preparations.